LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc.

LENZ·NASDAQ

$7.01

-0.14%
HealthcareBiotechnology

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

At a Glance

Live Snapshot
Market Cap$219.79M
EPS-2.8500
P/E Ratio-2.46
Earnings Date07/29/2026

lenz

Research Development Expenses

Last Annual Value

18.67M

3-Year CAGR

-4%

5-Year CAGR

15%

10-Year CAGR

%

LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc. Competitors Analysis of research-development-expenses

LENZ · NASDAQ
Companyresearch-development-expenses
CAGR 3Y
CAGR 5Y
CAGR 10Y
18.67M
-32.0%-13.2%N/A 
SVRA logo
Savara Inc.
NASDAQ:SVRA
81.40M
22.5%22.9%25.8%
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
61.53M
12.0%32.6%20.6%
13.18M
-13.4%-8.3%N/A
25.24M
-30.0%-17.4%-8.5%
73.72M
-16.2%-3.0%15.1%
23.33M
10.5%8.9%N/A
102.93M
18.1%37.9%N/A
160.64M
2.8%17.9%N/A
LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc. Fair Value Envelope

LENZ · NASDAQ

Our analysis suggests that LENZ has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $7.01, this represents a potential HIDDEN relative to our calculated worth for LENZ Therapeutics, Inc..

Intrinsic Value
Current Price: $7.01